Inventiva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Inventiva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs. Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva's leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held on January 13-16, 2025 at the Westin St. Francis in San Francisco, California.
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to present a corporate overview, and will engage, with Inventiva's leadership team, in investor meetings at the upcoming 43rd Annual J.P. Morgan Annual Healthcare Conference, being held on January 13-16, 2025 at the Westin St. Francis in San Francisco, California.
The event details are as follows:
The event details are as follows:
| Date: | Wednesday, January 15, 2025 |
| Time of the presentation: | 3:45pm (PST)/6:45pm (EST) |
| Live and replay link: | |
| Location: | The Westin St. Francis Hotel, San Francisco, California |
| Date: | Wednesday, January 15, 2025 |
| Time of the presentation: | 3:45pm (PST)/6:45pm (EST) |
| 直播及重播链接： | |
| 地点： | 美国加利福尼亚州旧金山西方圣弗朗西斯酒店 |
About Inventiva
关于Inventiva：Inventiva是一家专注于开发用于治疗MASH/NASH患者和其他具有重大未满足医疗需求的疾病的口服小分子疗法的临床前期生物技术公司。该公司在核受体、转录因子和表观遗传调控领域拥有丰富的专业知识和经验。Inventiva目前正在推进一个临床候选药物，拥有两个临床前项目的管线，并继续探索其他发展机会，以增加其管线。
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate and has a pipeline of two preclinical programs.
Inventiva是一家临床阶段的生物制药公司，专注于研发用于治疗患有MASH/NASH及其他有显著未满足医疗需求疾病的患者的口服小分子疗法。该公司在靶向核受体、转录因子和表观遗传调控方面具备强大的专业知识和经验。Inventiva目前正在推进一种临床候选药物，并拥有两个临床前项目的研发管线。
Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease.
Inventiva的核心产品候选药物Lanifibranor正处于关键性3期临床试验NATiV3阶段，用于治疗成年MASH/NASH慢性肝病患者。
Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.
Inventiva的管线还包括odiparcil，这是一种用于治疗成人MPS VI患者的药物候选者。作为Inventiva决定集中临床精力于lanifibranor开发的一部分，它暂停了与odiparcil相关的临床工作，并正在审查与其潜在进一步开发相关的可用选择。Inventiva还在选择其Hippo信号通路项目的候选者。
The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
该公司拥有约90人的科研团队，具有生物学、药物和计算化学、药物动力学和药理学以及临床开发领域的深厚专业知识。它拥有一个约240,000种药理相关分子的庞大库，其中约60%为自主研发，另外还拥有一个全资的研发设施。
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). .
Inventiva是一家上市公司，注册在巴黎泛欧交易所的规范市场B类（代码：IVA，ISIN：FR0013233012），并在美国的纳斯达克全球市场上市（代码：IVA）。
Contacts
联系人
|
Inventiva Pascaline Clerc EVP, Strategy and Corporate Affairs media@inventivapharma.com +1 202 499 8937 |
Brunswick Group Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau Media relations inventiva@brunswickgroup.com +33 1 53 96 83 83 |
Westwicke, an ICR Company Patricia L. Bank Investor relations patti.bank@westwicke.com +1 415 513 1284 |
| Inventiva 帕斯卡琳·克莱尔 执行副总裁，策略与公司事务 media@inventivapharma.com +1 202 499 8937 |
布伦瑞克集团 特里斯坦·罗克·蒙特冈 / 奥德·勒普勒克 / 拉菲·凯列托 媒体关系 inventiva@brunswickgroup.com +33 1 53 96 83 83 |
Westwicke，ICR公司 Patricia L. Bank 投资者关系 patti.bank@westwicke.com +1 415 513 1284 |
Attachment
附件
- Inventiva - PR - Annual JPM Healthcare Conference - EN - 12 17 2025
- Inventiva - PR - 年度JPm医疗会议 - 英文 - 2025年12月17日
